Repatha Alternatives: Six Options Compared

The main ones are Praluent, Leqvio, Lipfendra, Lerochol, bempedoic acid and ezetimibe. Repatha lowers LDL by about 60% and has outcomes trials, so people usually look elsewhere for cost or coverage, needles, side effects, or because they need less LDL lowering.

Praluent (alirocumab). It is the same kind of antibody that blocks PCSK9, with similar LDL lowering. You self-inject it every 2 weeks, or a higher dose every 4 weeks.

In ODYSSEY OUTCOMES, nearly 19,000 people who had recently had a heart attack or unstable angina took Praluent or placebo on top of a statin. Praluent lowered the risk of major cardiovascular events by 15%. Insurers often cover one of the two and not the other.

Leqvio (inclisiran) is an siRNA that tells the liver to make less PCSK9. A healthcare professional gives it once, again at 3 months, then every 6 months. It lowered LDL by about 50% in its main trials, and its outcomes trials have not reported as of October 2026.

Lipfendra (enlicitide), approved in July 2026, is the first oral PCSK9 inhibitor. It lowered LDL by 56% and 59% versus placebo at 24 weeks in the CORALreef trials. It launched at a list price of $315 a month, and its outcomes trial is underway.

Lerochol (lerodalcibep) is a once-monthly self-injection that can stay at room temperature for up to three months. It lowered LDL by about 56% versus placebo over a year, has a direct cash price of $199 a month, and has no outcomes results yet.

Bempedoic acid (Nexletol) lowers LDL by about 20%, versus about 60% for Repatha, so it fits best when you are relatively close to your goal. In CLEAR Outcomes, about 14,000 people who could not take statins had about 21% lower LDL than placebo and 13% fewer major cardiovascular events.

The 2026 ACC/AHA multisociety guideline elevated bempedoic acid to a first-line non-statin option.

Ezetimibe is usually the least expensive option. It is a generic daily pill that blocks cholesterol absorption in the gut and typically lowers LDL by roughly 20 to 25% when added to a statin. In IMPROVE-IT, adding it to a statin after a heart attack or unstable angina modestly lowered cardiovascular events.

Among PCSK9 options, Lerochol has a $199 a month direct cash price as of October 2026, and Repatha itself has Amgen's AmgenNow cash program.

No trial compares them head to head, so none can be called easier to tolerate. Label figures come from different trials, so use them as a list of things to ask about. Injection-site reactions ran 5.7% versus 5.0% on placebo for Repatha, 7.2% versus 5.1% for Praluent, 8% versus 2% for Leqvio, and 12% versus 5% for Lerochol.

The pills avoid injection-site reactions. Bempedoic acid's label lists higher uric acid, gout and tendon rupture (0.5% versus 0% in the cholesterol trials), so ask your clinician first if you have tendon problems.